Bachem strategy in peptide manufacturing, shares on SIX in sector comparison

Bachem focuses on its long-term role as a specialist in peptide and oligonucleotide active ingredients. The Swiss-listed shares sit in the broader pharma and biotech peer group on SIX as investors assess the business model and sector context.

By Stefan Krueger, Long-Term & Business Model desk. Reviewed prior to publication on 2026-06-28, 10:14.

Bachem Holding AG (CH0012530207) operates as a specialized manufacturer of active pharmaceutical ingredients for the global life-science industry. The shares trade on the SIX Swiss Exchange in Zurich, placing the stock in the Swiss-listed pharma and biotech peer group alongside names such as Lonza and Siegfried.

Position in Swiss life sciences

Bachem's core activity is the development and production of peptide and oligonucleotide active ingredients used by pharmaceutical and biotech companies in research and commercial drugs. These active ingredients form the basis for innovative therapies in fields such as oncology, metabolic diseases, and rare disorders, where targeted molecules are required. The company focuses on customer projects that range from early-stage clinical candidates to fully commercialized drugs.

Peers in Switzerland such as Lonza and Siegfried also operate as contract development and manufacturing organizations, offering services from process development to large-scale manufacturing for originator pharmaceutical firms. This broader CDMO segment has attracted investor attention over the past decade due to its asset-light, service-focused business model and steady demand from global pharma clients.

Long-term returns and shareholder perspective

Over a five-year horizon, Bachem Holding shareholders have seen a markedly positive total return, with one analysis citing a total shareholder return of around 151 percent over that period, compared with a share price gain of roughly 139 percent. That performance reflects reinvested dividends and the compounding effect of long-term growth in the company’s operations. The same analysis notes a more muted 6.5 percent return over the most recent twelve months, underlining that shorter periods can differ from the long-run trajectory.

In the most recent quarter, the shares experienced a drawdown of about 19 percent, according to that source, illustrating the volatility that can accompany growth expectations in the biotech and CDMO space. Investors comparing Bachem with other sector names such as Lonza, Siegfried or global peers often look beyond this quarterly move and concentrate on order book visibility, client diversification and regulatory track record.

The product behind the stock

Bachem’s representative product offering is custom-manufactured peptide active pharmaceutical ingredients tailored to specific client molecules. These peptides are produced under Good Manufacturing Practice conditions and supplied to pharmaceutical companies for clinical trials and commercial medicines, forming a crucial part of targeted therapies and hormone-based treatments.

Where the stock trades today

The Bachem shares (CH0012530207) trade on the SIX Swiss Exchange in Zurich; the current price in Swiss francs and the precise time stamp are available via the official exchange data and the company’s Investor Relations section.

Key data on the Bachem shares

• Company: Bachem Holding AG
• ISIN: CH0012530207
• WKN: 907488
• Ticker: BANB
• Trading venue: SIX Swiss Exchange
• Price (as of 2026-06-26, 17:30): 62.00 CHF
• Market cap: 4.1 billion CHF (as of 2026-06-26)
• Sector / industry: Pharmaceuticals, Biotechnology, Life-science manufacturing
• Index membership: SPI
• Next earnings date: not officially scheduled

Disclaimer: This text is for informational purposes only and does not constitute investment advice, a buy or sell recommendation, or any form of financial product consultation. Investors should conduct their own research or consult a licensed advisor before making investment decisions.